Henry Schein Stock (US42548G1040): Set to Report Q1 2026 Results Today

Henry Schein is scheduled to publish its first-quarter 2026 earnings on April 30, ahead of market open. Investors await updates on dental and medical distribution amid resilient U.S. demand and AI-driven sector trends.

Henry Schein Inc. is set to report its first-quarter results for 2026 on April 30, 2026, ahead of the market open, according to the company's investor relations schedule.Henry Schein IR page dated April 2026. The release will provide insights into the company's performance in dental, medical and animal health distribution during the three months ended March 31, 2026.

As of: April 30, 2026

By the AD HOC NEWS Editorial Team.

Henry Schein's business model in brief

Henry Schein, listed on Nasdaq under ticker HSIC with ISIN US42548G1040, operates as a leading global distributor of healthcare products and services. The company serves dental, medical, animal health and laboratory practices through a vast network of distribution centers primarily in North America, Europe and Asia. In its most recent full-year guidance from the Q4 2025 earnings release dated February 26, 2026, Henry Schein projected fiscal 2026 net sales growth of 3% to 6%, with adjusted diluted EPS between $5.30 and $5.60.Henry Schein Q4 2025 earnings release dated 02/26/2026.

The Dental Distribution segment, which accounts for the majority of revenue, supplies equipment, consumables and technology to over 1 million customers worldwide. Medical Distribution focuses on physician offices and pharmacies, while Global Veterinary Supply serves animal health professionals. Technology and Value-Added Services provide software and practice management solutions. The company's model emphasizes high-volume, low-margin distribution with recurring revenue from consumables.

Henry Schein generates the bulk of its revenue in the U.S., with international operations contributing steady growth. Fiscal 2025 net sales reached $12.6 billion, up 4% from prior year, per the annual report filed March 2026.Henry Schein 10-K for fiscal 2025.

What the latest development means for Henry Schein

The upcoming Q1 2026 report, scheduled for release before market open on April 30, 2026, marks the first quarterly update of the fiscal year. Investors will watch for commentary on U.S. healthcare spending resilience, supply chain dynamics and any impact from broader economic trends like rising retail sales and business activity. A conference call with management is set for 10:00 a.m. ET following the release, per the IR calendar.

In its latest official guidance from February 2026, Henry Schein outlined expectations for steady demand in core segments. The company previously noted that dental procedures remained robust into early 2026, supported by pent-up demand post-pandemic. Medical distribution benefited from physician office restocking, while veterinary sales saw gains from pet ownership trends.

Market context shows U.S. equities rallying amid AI investment tailwinds, with the S&P 500 up sharply since late March 2026, according to Goldman Sachs Research on April 24, 2026.Goldman Sachs report dated 04/24/2026. Healthcare distributors like Henry Schein could see indirect benefits from infrastructure spending linked to technology adoption in medical practices.

Why Henry Schein matters for U.S. investors

As a Nasdaq-listed company headquartered in Melville, New York, Henry Schein derives approximately 60% of its revenue from the U.S. market, making it a direct play on American healthcare distribution. The firm files regular SEC reports, including 10-Q and 8-K forms, providing transparency for U.S. retail investors. Its inclusion in healthcare ETFs and indices offers exposure via familiar vehicles like the S&P MidCap 400.

Henry Schein's scale—serving nearly 100% of U.S. dental practices—positions it as a bellwether for sector health. U.S. operations face domestic regulatory oversight from the FDA and FTC, alongside reimbursement dynamics from Medicare and private insurers. Recent U.S. retail sales jumped 1.7% in March 2026, the strongest in over three years, signaling consumer strength that bolsters elective dental and veterinary spending, per T. Rowe Price weekly update.T. Rowe Price update April 2026.

The company's dollar-denominated reporting and Nasdaq trading align with U.S. investor preferences. Volatility in broader markets, such as the NYSE Composite down 0.31% recently, underscores the appeal of defensive healthcare plays.NYSE.com as of April 30, 2026.

Risks and open questions for Henry Schein

Key risks include supply chain disruptions from geopolitical tensions, such as the U.S.-Iran conflict noted in market commentary, which could elevate input costs for imported medical goods. Labor shortages in distribution and inflationary pressures on wages remain concerns, as highlighted in recent PMI data showing rising output prices.

Open questions for the Q1 report center on margin performance amid higher freight and energy costs. Investors may seek clarity on international exposure, particularly in Europe, where currency fluctuations could impact results. Competitive dynamics from peers like Patterson Companies add pressure on market share.

Broader equity risks, including elevated oil prices testing inflation control, could indirectly affect healthcare spending if central banks delay rate cuts, per BlackRock commentary.BlackRock weekly commentary April 2026.

Bottom line

Henry Schein's scheduled Q1 2026 earnings release on April 30 provides a key read on early-year performance in healthcare distribution. With U.S. economic indicators pointing to resilience, the report and conference call will offer fresh guidance amid a rallying market backdrop.

Disclaimer: This is not investment advice. Stocks are volatile financial instruments.